

# Study of effect of gabapentin on persistent pain after open inguinal hernia repair

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 18/10/2016	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Jonathan Valentine

**Contact details**  
Pain Management Centre  
West Norwich Hospital  
Bowthorpe Road  
Norwich  
United Kingdom  
NR2 3TU  
+44 (0)1603 288450  
[jon.valentine@pain-expert.org](mailto:jon.valentine@pain-expert.org)

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N0547083244

# Study information

## Scientific Title

Study of effect of gabapentin on persistent pain after open inguinal hernia repair

## Study objectives

To establish whether gabapentin at a dose of 900-1800 mg per day is effective at reducing persistent pain after open inguinal hernia repair.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

## Health condition(s) or problem(s) studied

Inguinal hernia

## Interventions

Randomised controlled trial: gabapentin at a dose of 900 - 1800 mg per day.

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Gabapentin

## Primary outcome measure

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

31/05/2000

**Completion date**

31/05/2003

## **Eligibility**

**Key inclusion criteria**

16 subjects, 16 controls

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

32

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

31/05/2000

**Date of final enrolment**

31/05/2003

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**West Norwich Hospital**  
Norwich  
United Kingdom  
NR2 3TU

## **Sponsor information**

### **Organisation**

Department of Health (UK)

### **Sponsor details**

Richmond House  
79 Whitehall  
London  
United Kingdom  
SW1A 2NL

### **Sponsor type**

Government

### **Website**

<http://www.doh.gov.uk>

## **Funder(s)**

### **Funder type**

Government

### **Funder Name**

Norfolk and Norwich University Hospital/Norwich Primary Care Trust (PCT) (UK) - East Norfolk and Waveney Research Consortium

## **Results and Publications**

### **Publication and dissemination plan**

Not provided at time of registration

### **Intention to publish date**

### **Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration